Endo International PLC (ENDP) Upgraded by BidaskClub to “Sell”
Endo International PLC (NASDAQ:ENDP) was upgraded by research analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a report issued on Friday.
A number of other research firms have also recently commented on ENDP. Canaccord Genuity set a $12.00 price objective on shares of Endo International PLC and gave the stock a “hold” rating in a research report on Thursday, June 8th. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of Endo International PLC in a research report on Thursday, June 8th. Stifel Nicolaus cut shares of Endo International PLC from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $22.00 to $15.00 in a research report on Friday, June 9th. ValuEngine cut shares of Endo International PLC from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, Mizuho reaffirmed a “buy” rating and set a $19.00 price objective (up from $18.00) on shares of Endo International PLC in a research report on Thursday, May 25th. Three analysts have rated the stock with a sell rating, sixteen have issued a hold rating and five have given a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $14.75.
Endo International PLC (NASDAQ:ENDP) traded up 1.04% during mid-day trading on Friday, reaching $8.72. 5,294,100 shares of the company’s stock traded hands. The stock’s market cap is $1.95 billion. Endo International PLC has a 1-year low of $7.41 and a 1-year high of $24.93. The firm has a 50-day moving average price of $10.47 and a 200-day moving average price of $11.43.
Endo International PLC (NASDAQ:ENDP) last released its earnings results on Tuesday, August 8th. The company reported $0.93 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.19. Endo International PLC had a negative net margin of 126.93% and a positive return on equity of 37.58%. The business had revenue of $875.73 million during the quarter, compared to analysts’ expectations of $832.66 million. During the same period last year, the business earned $0.86 earnings per share. The firm’s revenue was down 4.9% on a year-over-year basis. Equities research analysts anticipate that Endo International PLC will post $3.52 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Endo International PLC (ENDP) Upgraded by BidaskClub to “Sell”” was first published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another site, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/08/19/endo-international-plc-endp-upgraded-by-bidaskclub-to-sell.html.
In related news, CFO Blaise Coleman purchased 6,500 shares of the company’s stock in a transaction that occurred on Tuesday, August 15th. The stock was acquired at an average price of $7.89 per share, with a total value of $51,285.00. Following the completion of the purchase, the chief financial officer now directly owns 13,729 shares in the company, valued at $108,321.81. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Terrance J. Coughlin purchased 20,000 shares of the company’s stock in a transaction that occurred on Thursday, August 10th. The stock was bought at an average cost of $7.70 per share, with a total value of $154,000.00. Following the purchase, the chief operating officer now owns 181,369 shares of the company’s stock, valued at $1,396,541.30. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 36,000 shares of company stock valued at $279,460. 0.50% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Macquarie Group Ltd. increased its position in Endo International PLC by 132.1% in the fourth quarter. Macquarie Group Ltd. now owns 6,500 shares of the company’s stock worth $107,000 after buying an additional 3,700 shares during the period. Hartford Investment Management Co. bought a new position in Endo International PLC during the first quarter worth approximately $1,363,000. Nationwide Fund Advisors increased its position in Endo International PLC by 400.0% in the first quarter. Nationwide Fund Advisors now owns 343,874 shares of the company’s stock worth $3,838,000 after buying an additional 275,101 shares during the period. First Quadrant L P CA bought a new position in Endo International PLC during the first quarter worth approximately $24,556,000. Finally, Russell Investments Group Ltd. increased its position in Endo International PLC by 13.8% in the first quarter. Russell Investments Group Ltd. now owns 269,453 shares of the company’s stock worth $3,008,000 after buying an additional 32,760 shares during the period. 92.27% of the stock is owned by institutional investors and hedge funds.
About Endo International PLC
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.